Announcement on Outline of Investor Reception Day
Filed with SSE · · 8 pages · Chinese
Summary by 6ix AI
The event aims to provide insights into the company's new product, a traditional Chinese medicine for treating tension-type headaches, which has recently been included in the national medical insurance list. Company executives and industry experts will participate, discussing the company's strategic plans and product development. The announcement emphasizes the company's commitment to innovation in traditional Chinese medicine and its future growth prospects.
Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries
Hunan Fangsheng Pharmaceutical Co., Ltd. on 6ix
Earlier from Hunan Fangsheng Pharmaceutical
- Announcement on Subsidiary's Passing GMP Compliance Inspection for Drugs
- Announcement on Resolutions of the 6th Extraordinary Meeting of the 6th Board of Directors in 2025
- Announcement on Holding Investor Reception Day
- Announcement on Inclusion of Innovative Traditional Chinese Medicine Yangxue Qufeng Zhitong Granules in the National Medical Insurance Catalog (2025)
- Announcement on Obtainment of the "Drug Registration Certificate" for Indobufen Tablets
Later from Hunan Fangsheng Pharmaceutical
- Announcement on Special Dividend in 2025
- Announcement on the Inspection Results of the Company's Transfer of Raw Material Production
- Announcement on Re-recognition of Wholly-owned Subsidiaries as High-tech Enterprises
- Announcement on Obtainment of the "Drug Registration Certificate" for Loxoprofen Sodium Cataplasm
- Announcement on Its Holding Subsidiary Obtaining the Drug Production License
Follow Hunan Fangsheng Pharmaceutical into a list and get an email when it puts out news.
Follow Hunan Fangsheng Pharmaceutical